Improving cell therapy for pancreatic cancer
Using Single-cell and Spatial Multi-omics to Improve Adoptive Cell Therapy against Pancreatic Cancer
This study is looking at ways to make T cell therapy work better for people with pancreatic cancer by understanding why T cells sometimes don’t function well in this type of tumor, using advanced techniques to find solutions that could help improve treatment results.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10949316 on NIH RePORTER |
What this research studies
This research investigates how to enhance the effectiveness of adoptive T cell therapy (ACT) for pancreatic cancer, a solid tumor where current treatments have struggled. By examining the molecular programming of T cells and the tumor microenvironment, the study aims to identify factors that cause T cell dysfunction. Using advanced techniques like single-cell multi-omics and spatial omics, researchers will analyze both mouse models and data from pancreatic cancer patients to uncover targetable mechanisms that could improve therapy outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer who are considering or undergoing adoptive T cell therapy.
Not a fit: Patients with other types of cancers or those who are not eligible for adoptive T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in enhancing adoptive T cell therapy for blood cancers, but this approach for solid tumors like pancreatic cancer is still largely untested.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Su, Yapeng — Fred Hutchinson Cancer Center
- Study coordinator: Su, Yapeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.